A detailed history of Brown Brothers Harriman & CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Brown Brothers Harriman & CO holds 86,429 shares of BMY stock, worth $5.03 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
86,429
Previous 93,540 7.6%
Holding current value
$5.03 Million
Previous $3.88 Million 15.14%
% of portfolio
0.03%
Previous 0.03%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$39.66 - $51.75 $282,022 - $367,994
-7,111 Reduced 7.6%
86,429 $4.47 Million
Q2 2024

Aug 09, 2024

SELL
$40.25 - $52.99 $80,942 - $106,562
-2,011 Reduced 2.1%
93,540 $3.88 Million
Q1 2024

May 10, 2024

SELL
$47.98 - $54.4 $110,306 - $125,065
-2,299 Reduced 2.35%
95,551 $5.18 Million
Q4 2023

Feb 12, 2024

SELL
$48.48 - $57.85 $109,904 - $131,145
-2,267 Reduced 2.26%
97,850 $5.02 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $82,551 - $92,304
-1,426 Reduced 1.4%
100,117 $5.81 Million
Q2 2023

Aug 07, 2023

SELL
$63.71 - $70.74 $698,643 - $775,734
-10,966 Reduced 9.75%
101,543 $6.49 Million
Q1 2023

May 11, 2023

SELL
$65.71 - $74.53 $252,063 - $285,897
-3,836 Reduced 3.3%
112,509 $7.8 Million
Q4 2022

Feb 09, 2023

BUY
$68.48 - $81.09 $1.61 Million - $1.91 Million
23,525 Added 25.34%
116,345 $8.37 Million
Q3 2022

Nov 10, 2022

BUY
$0.13 - $76.84 $547 - $323,419
4,209 Added 4.75%
92,820 $6.6 Million
Q2 2022

Aug 11, 2022

SELL
$72.62 - $79.98 $26,942 - $29,672
-371 Reduced 0.42%
88,611 $6.82 Million
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $109,065 - $130,779
-1,774 Reduced 1.95%
88,982 $6.5 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $820,753 - $956,806
-15,304 Reduced 14.43%
90,756 $5.66 Million
Q3 2021

Nov 15, 2021

SELL
$59.17 - $69.31 $666,727 - $780,985
-11,268 Reduced 9.6%
106,060 $6.28 Million
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $16,653 - $18,135
269 Added 0.23%
117,328 $7.84 Million
Q1 2021

May 13, 2021

BUY
$59.34 - $66.74 $80,761 - $90,833
1,361 Added 1.18%
117,059 $7.39 Million
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $171,891 - $194,785
2,977 Added 2.64%
115,698 $7.18 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $131,629 - $145,862
-2,292 Reduced 1.99%
112,721 $6.8 Million
Q2 2020

Aug 13, 2020

SELL
$54.82 - $64.09 $446,015 - $521,436
-8,136 Reduced 6.61%
115,013 $6.76 Million
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $424,745 - $617,254
9,154 Added 8.03%
123,149 $6.86 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $583,778 - $761,485
11,863 Added 11.62%
113,995 $7.32 Million
Q3 2019

Nov 14, 2019

BUY
$42.77 - $50.71 $283,051 - $335,598
6,618 Added 6.93%
102,132 $5.18 Million
Q2 2019

Aug 14, 2019

SELL
$44.62 - $49.34 $69,294 - $76,625
-1,553 Reduced 1.6%
95,514 $4.33 Million
Q1 2019

May 15, 2019

SELL
$45.12 - $53.8 $38,667 - $46,106
-857 Reduced 0.88%
97,067 $4.63 Million
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $777,819 - $1.01 Million
15,952 Added 19.46%
97,924 $5.09 Million
Q3 2018

Nov 14, 2018

BUY
$55.19 - $62.25 $196,917 - $222,108
3,568 Added 4.55%
81,972 $5.09 Million
Q2 2018

Aug 14, 2018

SELL
$50.53 - $62.98 $630,159 - $785,423
-12,471 Reduced 13.72%
78,404 $4.34 Million
Q1 2018

May 14, 2018

SELL
$59.92 - $68.98 $5,213 - $6,001
-87 Reduced 0.1%
90,875 $5.75 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $52,747 - $57,507
880 Added 0.98%
90,962 $5.57 Million
Q3 2017

Nov 14, 2017

SELL
$55.23 - $63.74 $210,591 - $243,040
-3,813 Reduced 4.06%
90,082 $5.74 Million
Q2 2017

Aug 14, 2017

BUY
N/A
93,895
93,895 $5.23 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Brown Brothers Harriman & CO Portfolio

Follow Brown Brothers Harriman & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brown Brothers Harriman & CO, based on Form 13F filings with the SEC.

News

Stay updated on Brown Brothers Harriman & CO with notifications on news.